This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Sanofi. Active years: 2014-2021.
Location History:
- Wildau, DE (2014 - 2016)
- Frankfurt-am-Main, DE (2021)
Company Filing History:
Years Active: 2014-2021
Title: Peter Wonerow: Innovator in Antibody Research
Introduction
Peter Wonerow is a notable inventor based in Wildau, Germany. He has made significant contributions to the field of antibody research, particularly in the development of innovative therapeutic agents. With a total of 3 patents to his name, Wonerow's work focuses on advancing treatments for various medical conditions, including cancer and vascular diseases.
Latest Patents
Wonerow's latest patents include groundbreaking inventions such as anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123. These inventions concern antibody-like binding proteins that target CD3 and at least one additional antigen, such as CD123. The patents also cover pharmaceutical compositions that utilize these antibodies for cancer treatment. Furthermore, Wonerow has developed antagonist antibodies and their Fab fragments against Glycoprotein VI (GPVI), which play a crucial role in preventing platelet activation and treating thrombosis and other vascular diseases.
Career Highlights
Peter Wonerow is currently employed at Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to collaborate with other experts in the field, enhancing the impact of his research and innovations. His contributions have been instrumental in advancing the understanding and treatment of various diseases through antibody technology.
Collaborations
Wonerow has worked alongside talented colleagues, including Katja Kroll and Christian Lange. Their collaborative efforts have further enriched the research environment and fostered innovation within their projects.
Conclusion
Peter Wonerow is a distinguished inventor whose work in antibody research has the potential to transform therapeutic approaches in medicine. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.